Recent Quotes

My Watchlist

Indicators

Astellas Pharma Inc (OP: ALPMF )

11.13 UNCHANGED

Streaming Delayed Price Updated: 10:23 AM EDT, Oct 31, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	11.13
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	11.13
Today's Range	11.13 - 11.13
52wk Range	9.170 - 12.74
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

October 16, 2024

William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales...

Via Benzinga

Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data

August 05, 2024

Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage...

Via Benzinga

Performance

YTD	-6.90%	-6.90%
1 Month	+1.67%	+1.67%
3 Month	+8.03%	+8.03%
6 Month	+10.89%	+10.89%
1 Year	-7.12%	-7.12%

More News

Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval

May 17, 2024

Via Benzinga

Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study

October 05, 2023

Via Benzinga

Astellas' Menopause Drug Under FDA Review

August 18, 2022

Via Benzinga

Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say

July 26, 2022

Via Benzinga

Why Is Seagen Stock Trading Higher Today?

September 22, 2023

Via Benzinga

What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?

September 20, 2023

Via Benzinga

Why Shares of Adaptive Biotechnologies Jumped This Week

June 16, 2023

Via The Motley Fool

Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles

June 08, 2023

Via Benzinga

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?

June 01, 2023

Via TheNewswire.com

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?

June 01, 2023

Via News Direct

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?

May 30, 2023

Via Benzinga

Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories

May 15, 2023

Via Benzinga

Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback

May 15, 2023

Via Benzinga

Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%

May 01, 2023

Via Benzinga

Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'

May 01, 2023

Via Benzinga

FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer

April 04, 2023

Via Benzinga

AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners

March 28, 2023

Via Benzinga

Japanese Government Urges China To Release Astellas Pharma's Employee

March 27, 2023

Via Benzinga

Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug

March 17, 2023

Via Benzinga

Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts

January 31, 2023

Via Benzinga

Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering

January 24, 2023

Via Benzinga

Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs

October 25, 2022

Via Benzinga

Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate

July 26, 2022

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.